TWST PE Ratio & Valuation,Is TWST Overvalued

TWST Relative Valuation

TWST's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TWST is overvalued; if below, it's undervalued.

Historical Valuation

Twist Bioscience Corp (TWST) is now in the Fair zone, suggesting that its current forward PS ratio of 4.42 is considered Fairly compared with the five-year average of -17.55. The fair price of Twist Bioscience Corp (TWST) is between 26.15 to 40.88 according to relative valuation methord.

Relative Value

Fair Zone

26.15-40.88

Current Price：31.13

Fair

-21.60

-40.05

EV/EBITDA

Twist Bioscience Corp. (TWST) has a current EV/EBITDA of -40.05. The 5-year average EV/EBITDA is -18.35. The thresholds are as follows: Strongly Undervalued below -45.42, Undervalued between -45.42 and -31.89, Fairly Valued between -4.81 and -31.89, Overvalued between -4.81 and 8.72, and Strongly Overvalued above 8.72. The current Forward EV/EBITDA of -40.05 falls within the Undervalued range.

-18.71

EV/EBIT

Twist Bioscience Corp. (TWST) has a current EV/EBIT of -18.71. The 5-year average EV/EBIT is -15.28. The thresholds are as follows: Strongly Undervalued below -38.96, Undervalued between -38.96 and -27.12, Fairly Valued between -3.44 and -27.12, Overvalued between -3.44 and 8.40, and Strongly Overvalued above 8.40. The current Forward EV/EBIT of -18.71 falls within the Historic Trend Line -Fairly Valued range.

4.42

Twist Bioscience Corp. (TWST) has a current PS of 4.42. The 5-year average PS is 13.56. The thresholds are as follows: Strongly Undervalued below -16.55, Undervalued between -16.55 and -1.49, Fairly Valued between 28.62 and -1.49, Overvalued between 28.62 and 43.67, and Strongly Overvalued above 43.67. The current Forward PS of 4.42 falls within the Historic Trend Line -Fairly Valued range.

233.28

P/OCF

Twist Bioscience Corp. (TWST) has a current P/OCF of 233.28. The 5-year average P/OCF is 129.72. The thresholds are as follows: Strongly Undervalued below -1402.56, Undervalued between -1402.56 and -636.42, Fairly Valued between 895.85 and -636.42, Overvalued between 895.85 and 1661.99, and Strongly Overvalued above 1661.99. The current Forward P/OCF of 233.28 falls within the Historic Trend Line -Fairly Valued range.

111.97

P/FCF

Twist Bioscience Corp. (TWST) has a current P/FCF of 111.97. The 5-year average P/FCF is -10.60. The thresholds are as follows: Strongly Undervalued below -112.02, Undervalued between -112.02 and -61.31, Fairly Valued between 40.11 and -61.31, Overvalued between 40.11 and 90.82, and Strongly Overvalued above 90.82. The current Forward P/FCF of 111.97 falls within the Strongly Overvalued range.

Twist Bioscience Corp (TWST) has a current Price-to-Book (P/B) ratio of 3.99. Compared to its 3-year average P/B ratio of 3.65 , the current P/B ratio is approximately 9.35% higher. Relative to its 5-year average P/B ratio of 4.87, the current P/B ratio is about -18.03% higher. Twist Bioscience Corp (TWST) has a Forward Free Cash Flow (FCF) yield of approximately -3.97%. Compared to its 3-year average FCF yield of -8.64%, the current FCF yield is approximately -54.00% lower. Relative to its 5-year average FCF yield of -7.60% , the current FCF yield is about -47.73% lower.

4.12

P/B

Median3y

3.65

Median5y

4.87

-3.97

FCF Yield

Median3y

-8.64

Median5y

-7.60

Competitors Valuation Multiple

The average P/S ratio for TWST's competitors is 0.00, providing a benchmark for relative valuation. Twist Bioscience Corp Corp (TWST) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 16.88%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of TWST decreased by 30.86% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 84.71M to 99.01M.

The secondary factor is the P/E Change, contributed -14.74%to the performance.

Overall, the performance of TWST in the past 1 year is driven by Revenue Growth. Which is more sustainable.

16.88%

84.71M → 99.01M

Revenue Growth

-33.00%

-40.91 → -27.41

Margin Expansion

-14.74%

-29.02 → -24.74

P/E Change

-30.86%

46.47 → 32.13

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Twist Bioscience Corp (TWST) currently overvalued or undervalued?

What is Twist Bioscience Corp (TWST) fair value?

TWST's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Twist Bioscience Corp (TWST) is between 26.15 to 40.88 according to relative valuation methord.

How does TWST's valuation metrics compare to the industry average?

What is the current P/B ratio for Twist Bioscience Corp (TWST) as of Dec 18 2025?

As of Dec 18 2025, Twist Bioscience Corp (TWST) has a P/B ratio of 3.99. This indicates that the market values TWST at 3.99 times its book value.

What is the current FCF Yield for Twist Bioscience Corp (TWST) as of Dec 18 2025?

As of Dec 18 2025, Twist Bioscience Corp (TWST) has a FCF Yield of -3.97%. This means that for every dollar of Twist Bioscience Corp’s market capitalization, the company generates -3.97 cents in free cash flow.

What is the current Forward P/E ratio for Twist Bioscience Corp (TWST) as of Dec 18 2025?

As of Dec 18 2025, Twist Bioscience Corp (TWST) has a Forward P/E ratio of -20.93. This means the market is willing to pay $-20.93 for every dollar of Twist Bioscience Corp’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Twist Bioscience Corp (TWST) as of Dec 18 2025?

As of Dec 18 2025, Twist Bioscience Corp (TWST) has a Forward P/S ratio of 4.42. This means the market is valuing TWST at $4.42 for every dollar of expected revenue over the next 12 months.

TWST Valuation

Overview

Forecast

Valuation

Earnings